Advertisement

Vitamin D deficiency and its association with fatigue and quality of life in multiple sclerosis patients

  • Yesim BeckmannEmail author
  • Sabiha Türe
  • Sule Uysal Duman
Research
  • 12 Downloads

Abstract

Background

Vitamin D deficiency is associated with the incidence and prevalence of a variety of neurologic disorders, including multiple sclerosis. However, available studies to date have not provided convincing evidence that vitamin D treatment improves fatigue and life quality in patients with multiple sclerosis.

Aim

To assess the relationship of vitamin D deficiency with health-related quality-of-life issues and fatigue in multiple sclerosis patients.

Methods

Vitamin D3 levels were measured in 149 multiple sclerosis patients. In patients with lower than 30 ng/mL levels, vitamin D was administered. Fatigue and health-related quality of life scores were measured at baseline and months 1, 3, 6, and 12 after the beginning of vitamin D3 administration.

Results

Among 149 patients, 90% were vitamin D deficient. After vitamin D supplementation, health-related quality of life and fatigue scores improved significantly. There was a direct association between health-related quality of life with absence of fatigue and vitamin D status at the end of study.

Conclusion

The 90% frequency of multiple sclerosis patients with vitamin D deficiency, together with the significant association of vitamin D status with the absence of fatigue and improved physical and functional well-being, points to vitamin D supplementation as a potential therapy to enhance the patient’s quality of life.

Relevance of the article for predictive, preventive, and personalized medicine

This article emphasizes that vitamin D supplementation can improve clinical outcome in multiple sclerosis patients providing immune modulation and neuroprotection. Identification and correction of vitamin D deficiency has the potential to treat the related quality of life in patients with multiple sclerosis.

Keywords

predictive preventive personalized medicine multiple sclerosis vitamin D health-related quality of life fatigue 

Notes

Author contribution

The authors (Yesim Beckmann and Sabiha Ture) contributed equally to the manuscript.

Compliance with ethical standards

Competing interests

The authors declare that they have no competing interests.

Ethical approval

The research did not involve any risk for the participants. All ethical guidelines were followed as required for conducting human research. The procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional research, the study being approved to be run by the manager of the Izmir Katip Celebi University, where the study was conducted and by the Committee for Ethical Research of Izmir Katip Celebi University (Ethical approval number 307/2016). The research complies with the provisions of the Declaration of Helsinki. All the participants gave their informed consent for the research, and their anonymity was preserved.

Consent for publication

Not applicable

References

  1. 1.
    Pawlitzki M, Neumann J, Kaufmann J, Stadler E, Sweeney-Reed C, Sailer M, et al. Loss of corticospinal tract integrity in early MS disease stages. Neurol Neuroimmunol Neuroinflamm. 2017;4(6):e399.CrossRefGoogle Scholar
  2. 2.
    Wang C, Barnett MH, Yiannikas C, Barton J, Parratt J, You Y, et al. Lesion activity and chronic demyelination are the major determinants of brain atrophy in MS. Neurol Neuroimmunol Neuroinflamm. 2019;6:e593.CrossRefGoogle Scholar
  3. 3.
    Zeydan B, Gu X, Atkinson EJ, Keegan BM, Weinshenker BG, Tillema JM, et al. Cervical spinal cord atrophy: an early marker of progressive MS onset. Neurol Neuroimmunol Neuroinflamm. 2018;5:e435.CrossRefGoogle Scholar
  4. 4.
    Penner IK, Paul F. Fatigue as a symptom or comorbidity of neurological diseases. Nat Rev Neurol. 2017;13(11):662–75.CrossRefGoogle Scholar
  5. 5.
    Lerdal A, Celius EG, Krupp L, Dahl AA. A prospective study of patterns of fatigue in multiple sclerosis. Eur J Neurol. 2007;14(12):1338–43.CrossRefGoogle Scholar
  6. 6.
    Dörr J, Döring A, Paul F. Can we prevent or treat multiple sclerosis by individualised vitamin D supply? EPMA J. 2013;4(1):4.CrossRefGoogle Scholar
  7. 7.
    Rotstein DL, Healy BC, Malik MT, Carruthers RL, Musallam AJ, Kivisakk P, et al. Effect of vitamin D on MS activity by disease-modifying therapy class. Neurol Neuroimmunol Neuroinflamm. 2015;2(6):e167.CrossRefGoogle Scholar
  8. 8.
    Kepczynska K, Zajda M, Lewandowski Z, Przedlacki J, Zakrzewska-Pniewska B. Bone metabolism and vitamin D status in patients with multiple sclerosis. Neurol Neurochir Pol. 2016;50(4):251–7.CrossRefGoogle Scholar
  9. 9.
    Polachini CR, Spanevello RM, Zanini D, Baldissarelli J, Pereira LB, Schetinger MR, et al. Evaluation of delta-aminolevulinic dehydratase activity, oxidative stress biomarkers, and vitamin D levels in patients with multiple sclerosis. Neurotox Res. 2016;29(2):230–42.CrossRefGoogle Scholar
  10. 10.
    Duan S, Lv Z, Fan X, Wang L, Han F, Wang H, et al. Vitamin D status and the risk of multiple sclerosis: a systematic review and meta-analysis. Neurosci Lett. 2014;5(70):108–13.CrossRefGoogle Scholar
  11. 11.
    Behrens JR, Rasche L, Gieß RM, Pfuhl C, Wakonig K, Freitag E, et al. Low 25-hydroxyvitamin D, but not the bioavailable fraction of 25-hydroxyvitamin D, is a risk factor for multiple sclerosis. Eur J Neurol. 2016;23:62–7.CrossRefGoogle Scholar
  12. 12.
    Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292–302.CrossRefGoogle Scholar
  13. 13.
    Holick M. Vitamin D deficiency. N EngJ Med 2007;266–81.CrossRefGoogle Scholar
  14. 14.
    Kurtzke JF. Rating neurologic impairment in multiple sclerosis An expanded disability status scale (EDSS). Neurology. 1983;33(11):1444–52.CrossRefGoogle Scholar
  15. 15.
    Armutlu K, Korkmaz NC, Keser I, Sumbuloglu V, Akbiyik DI, Guney Z, et al. The validity and reliability of the Fatigue Severity Scale in Turkish multiple sclerosis patients. Int J Rehabil Res. 2007;30(1):81–5.CrossRefGoogle Scholar
  16. 16.
    Ozakbas S, Ormeci B, Idiman E. Utilization of the Multiple Sclerosis Functional Composite in Follow-up: Relationship to Disease Phenotype, Disability and Treatment Strategies. J Neurol Sci. 2005;232:65–9.CrossRefGoogle Scholar
  17. 17.
    Golubnitschaja O, Baban B, Boniolo G, Wang W, Bubnov R, Kapalla M, et al. Medicine in the early twenty-first century: paradigm and anticipation - EPMA position paper 2016. EPMA J. 2016;7:23.CrossRefGoogle Scholar
  18. 18.
    Golubnitschaja O, Costigliola V, EPMA. General report & recommendations in predictive, preventive and personalised medicine 2012: white paper of the European association for predictive, preventive and personalised medicine. EPMA J. 2012;3(1):14.CrossRefGoogle Scholar
  19. 19.
    Veauthier C, Paul F. Sleep disorders in multiple sclerosis and their relationship to fatigue. Sleep Med. 2014;15:5–14.CrossRefGoogle Scholar
  20. 20.
    Pöttgen J, Moss MR, Wendebourg MJ, Feddersen LK, Lau S, Köpke S, Meyer B, Friede T, Penner IK,Heesen C, Gold SM. Randomised controlled trial of a self-guided online fatigue intervention in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2018;1–7.Google Scholar
  21. 21.
    Gaede G, Tiede M, Lorenz I, Brandt AU, Pfueller C, Dörr J, et al. Safety and preliminary efficacy of deep transcranial magneticstimulation in MS-related fatigue. Neurol Neuroimmunol Neuroinflamm. 2017;5(1):e423.CrossRefGoogle Scholar
  22. 22.
    Brenton JN, Banwell B, Bergqvist AGC, Lehner-Gulotta D, Gampper L, Leytham E, et al. Pilot study of a ketogenic diet in relapsing- remitting MS. Neurol Neuroimmunol Neuroinflamm. 2019;6:e565.CrossRefGoogle Scholar
  23. 23.
    Coe S, Cossington J, Collett J, Soundy A, Izadi H, Ovington M, et al. A randomised double-blind placebo-controlled feasibility trialof flavonoid-rich cocoa for fatigue in people with relapsing and remittingmultiple sclerosis. J Neurol Neurosurg Psychiatry. 2019;90(5):507–13.CrossRefGoogle Scholar
  24. 24.
    Camu W, Lehert P, Pierrot-Deseilligny C, Hautecoeur P, Besserve A, Jean Deleglise AS, et al. Cholecalciferol in relapsing-remitting MS: A randomized clinical trial(CHOLINE). Neurol Neuroimmunol Neuroinflamm. 2019;6(5):e597.CrossRefGoogle Scholar
  25. 25.
    Jagannath VA, Filippini G, Di Pietrantonj C, Asokan GV, Robak EW, Whamond L, et al. Vitamin D for the management of multiple sclerosis. Cochrane Database Syst Rev. 2018;9:CD008422.PubMedGoogle Scholar
  26. 26.
    Koduah P, Paul F, Dörr JM. Vitamin D in the prevention, prediction and treatment of neurodegenerative and neuroinflammatory diseases. EPMA J. 2017;8(4):313–25.CrossRefGoogle Scholar
  27. 27.
    Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA. 2006;296:2832–8.CrossRefGoogle Scholar
  28. 28.
    Martinelli V, Dalla Costa G, Colombo B, Dalla Libera D, Rubinacci A, Filippi M, et al. Vitamin D levels and risk of multiple sclerosis in patients with clinically isolated syndromes. Mult Scler. 2014;20(2):147–55.CrossRefGoogle Scholar
  29. 29.
    Mowry EM, Krupp LB, Milazzo M, Chabas D, Strober JB, Belman AL, et al. Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol. 2010;67(5):618–24.PubMedGoogle Scholar
  30. 30.
    Simpson S, Taylor B, Blizzard L, Simpson S Jr, Taylor B, Blizzard L, et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol. 2010;68(2):193–203.PubMedGoogle Scholar
  31. 31.
    Ascherio A, Munger KL, White R, Köchert K, et al. Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol. 2014;71(3):306–14.CrossRefGoogle Scholar
  32. 32.
    Fitzgerald KC, Munger KL, Köchert K, et al. Association of vitamin D levels with multiple sclerosis activity andprogression in patients receiving Interferon Beta-1b. JAMA Neurol. 2015;72(12):1458–65.CrossRefGoogle Scholar
  33. 33.
    Achiron A, Givon U, Magalashvili D, Dolev M, Liraz Zaltzman S, Kalron A, et al. Effect of Alfacalcidol on multiple sclerosis-related fatigue: A randomized, double-blind placebo-controlled study. Mult Scler. 2015;21(6):767–75.CrossRefGoogle Scholar
  34. 34.
    Ashtari F, Toghianifar N, Zarkesh-Esfahani SH, Mansourian M. High dose Vitamin D intake and quality of life in relapsing-remitting multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Neurol Res. 2016;38(10):888–92.CrossRefGoogle Scholar
  35. 35.
    Golan D, Halhal B, Glass-Marmor L, Staun-Ram E, Rozenberg O, Lavi I, et al. Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties. BMC Neurol. 2013;13:60.CrossRefGoogle Scholar
  36. 36.
    Kampman MT, Steffensen LH, Mellgren SI, Jorgensen L. Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double- blind randomised controlled trial. Mult Scler. 2012;18(8):1144–51.CrossRefGoogle Scholar
  37. 37.
    Smith MM, Arnett PA. Factors related to employment changes in individuals with multiple sclerosis. Mult Scler. 2005;11(5):602–9.CrossRefGoogle Scholar
  38. 38.
    Veauthier C, Hasselmann H, Gold SM, Paul F. The Berlin Treatment Algorithm: recommendations for tailored innovative therapeutic strategies for multiple sclerosis- related fatigue. EPMA J. 2016;7:25.CrossRefGoogle Scholar
  39. 39.
    Veauthier C, Radbruch H, Gaede G, Pfueller C, Dorr J, Bellmann-Strobl J, et al. Fatigue in multiple sclerosis is closely related to sleep disorders: a polysomnographic cross-sectional study. Mult Scler. 2011;17(5):613–22.CrossRefGoogle Scholar
  40. 40.
    Kaminska M, Kimoff R, Benedetti A, Robinson A, Bar-Or A, Lapierre Y, et al. Obstructive sleep apnea is associated with fatigue in multiple sclerosis. Mult Scler. 2012;18(8):1159–69.CrossRefGoogle Scholar

Copyright information

© European Association for Predictive, Preventive and Personalised Medicine (EPMA) 2019

Authors and Affiliations

  1. 1.Department of Neurology, Medical Facultyİzmir Katip Celebi UniversityİzmirTurkey

Personalised recommendations